212 related articles for article (PubMed ID: 16958819)
21. Jumping exercises with and without raloxifene treatment in healthy elderly women.
Von Heideken Wågert P; Littbrand H; Johansson A; Nordström P; Gustafson Y
J Bone Miner Metab; 2002; 20(6):376-82. PubMed ID: 12434166
[TBL] [Abstract][Full Text] [Related]
22. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
Maddalozzo GF; Widrick JJ; Cardinal BJ; Winters-Stone KM; Hoffman MA; Snow CM
Bone; 2007 May; 40(5):1244-51. PubMed ID: 17291843
[TBL] [Abstract][Full Text] [Related]
23. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.
Heilberg IP; Hernandez E; Alonzo E; Valera R; Ferreira LG; Gomes SA; Bellorin-Font E; Weisinger JR
Ren Fail; 2005; 27(2):155-61. PubMed ID: 15807179
[TBL] [Abstract][Full Text] [Related]
26. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
27. [Alternatives to hormone replacement therapy: raloxifene and tibolone].
von Holst T
Z Arztl Fortbild Qualitatssich; 2000 Apr; 94(3):205-9. PubMed ID: 10802895
[TBL] [Abstract][Full Text] [Related]
28. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
29. Lipid profiles and bone mineral density in pre- and postmenopausal women in Korea.
Jeong IK; Cho SW; Kim SW; Choi HJ; Park KS; Kim SY; Lee HK; Cho SH; Oh BH; Shin CS
Calcif Tissue Int; 2010 Dec; 87(6):507-12. PubMed ID: 20976443
[TBL] [Abstract][Full Text] [Related]
30. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
31. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
Vignot E; Meunier PJ
Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
[TBL] [Abstract][Full Text] [Related]
32. Difference in bone acquisition among hormonally treated postmenopausal women with normal and low bone mass.
Taechakraichana N; Jaisamrarn U; Panyakhamlerd K; Chaikittisilpa S; Limpaphayom K
J Med Assoc Thai; 2001 Oct; 84 Suppl 2():S586-92. PubMed ID: 11853286
[TBL] [Abstract][Full Text] [Related]
33. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
34. Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy.
Kawai H; Furuhashi M; Suganuma N
Arch Gynecol Obstet; 2004 Mar; 269(3):192-5. PubMed ID: 13680264
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women.
Hart DM; Farish E; Fletcher CD; Barnes JF; Hart H; Nolan D; Spowart K
Osteoporos Int; 1998; 8(4):326-32. PubMed ID: 10024902
[TBL] [Abstract][Full Text] [Related]
36. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
[TBL] [Abstract][Full Text] [Related]
37. Differential associations of residual estradiol levels with bone mineral density and serum lipids in postmenopausal women with osteoporosis.
Ongphiphadhanakul B; Chanprasertyothin S; Chailurkit L; Chansirikarn S; Puavilai G; Rajatanavin R
Maturitas; 2004 Jul; 48(3):193-6. PubMed ID: 15207884
[TBL] [Abstract][Full Text] [Related]
38. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
Legroux-Gerot I; Vignau J; Collier F; Cortet B
Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
[TBL] [Abstract][Full Text] [Related]
39. Relationships between body composition, muscular strength, and bone mineral density in estrogen-deficient postmenopausal women.
Sherk VD; Palmer IJ; Bemben MG; Bemben DA
J Clin Densitom; 2009; 12(3):292-8. PubMed ID: 19155180
[TBL] [Abstract][Full Text] [Related]
40. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.
Levy C; Harnois DM; Angulo P; Jorgensen R; Lindor KD
Liver Int; 2005 Feb; 25(1):117-21. PubMed ID: 15698408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
